Locate Available Clinical Trials

To view available Clinical Trial information choose from the list on the right or search using the fields below.



trial #
trial description
  • Alliance A071401
  •  The purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered genes. Today, treatment for meningioma is the same for all patients, and is not based on tumor genetic testing. This study is trying to see if tumor genetic testing would be helpful at guiding treatment in patients such as you.

  • Alliance A221208
  • Usually the first treatment for brain radionecrosis only works for some patients and can cause significant side effects in many patients. The purpose of this study is test whether adding a drug called bevacizumab to your standard corticosteroid therapy will improve your symptoms over corticosteroid therapy alone by improving the radionecrosis and minimizing treatment-related side effects. The effects of bevacizumab with standard corticosteroid therapy will be compared to a placebo with standard corticosteroid therapy.

  • CTSU EAF151
  • The purpose of this research study is to test whether the advanced perfusion MRI done prior to starting Bevacizumab and a few weeks after starting Bevacizumab can determine your response to the treatment better than the standard MRI performed at typical time points. The researchers want to see if this type of advanced MRI is better or the same as what is usually used for monitoring your brain cancer.


     In this research study you are being asked to have two MRI scans, one right before starting Bevacizumab (first dose) and another right before your second dose of Bevacizumab. The dynamic susceptibility contrast (DSC) MRI is also sometimes referred to as an advanced perfusion MRI. This is an existing standard of clinical practice at some centers, and optional at others. Some centers do not perform this. It will be performed with a contrast agent called gadolinium-based contrast agent (Gadavist) to help evaluate changes in the blood vessels within the cancer.

    p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 14.0px Geneva; -webkit-text-stroke: #000000} span.s1 {font-kerning: none}

  • NRG BN003
  • The purpose of this study is to compare any good and bad effects of using radiation to treat a meningioma that has been completely removed compared with the more common approach of observing the tumor and treating it with radiation if it returns. Using radiation before the tumor returns could prevent it from returning but it could also cause side effects. This study will allow the researchers to know whether this usual approach (treating you with radiation) is better, the same, or worse than the other usual approach (observation after surgery). 

  • NRG BN005
  • The purpose of this study is to compare any good and bad effects of using proton therapy to using photon therapy.  Photon therapy is the usual treatment approach for your brain cancer. Proton therapy uses a beam of proton particles to send radiation inside the body to the tumor. This study will allow the researchers to know whether proton therapy is better, the same, or worse than the usual approach. Proton therapy may have less negative effects on brain function than photons because less brain is exposed to radiation when proton therapy is used. However, proton therapy might also be associated with more frequent tumor recurrences. After receiving protons or photons, both groups will receive a usual chemotherapy, temozolomide. To be eligible for this study, your tumor must have a mutation in a gene called IDH. The study team will verify that your tumor has an IDH mutation. To be better, proton therapy should result in less decline in your thinking skills months to years after treatment. 

  • NRG/RTOG 1122
  • The purpose of this study is to find out the effect of bevacizumab with or without a new research drug, AMG 386, on glioblastoma or gliosarcoma. Bevacizumab is a protein that works by preventing new cancer-related blood vessel formation. The U.S. Food and Drug Administration (called FDA) has approved bevacizumab for the treatment of recurrent glioblastoma. However, treatment with bevacizumab alone has only modestly improved overall survival in patients with this type of brain tumor. For this reason other drugs, such as AMG 386, are being evaluated.